The trajectory of Sildenafil presents a complex picture for shareholders. While the initial launch generated significant gains, the end of its exclusive rights opened the avenue to generic competitors, dramatically https://bookmarkwuzz.com/story21643735/sildenafil-and-big-pharma-a-volatile-investment